Evidence map›Paper›PMID 32337233›Full record

ArticleBioMed research international2020

Effects of the Bone/Bone Marrow Microenvironments on Prostate Cancer Cells and CD59 Expression.

Bo Yan, Yan Li, Shaoju Min, Peng Zhang, Bin Xu, Zhen Wang, Wei Zhang, Jiasheng Chen, Guangheng Luo, Chunxiao Liu

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Bo YanDepartment of Urology, Guizhou Provincial People's Hospital, Medical College of Guizhou University, Guiyang, Guizhou, China.
Yan LiDepartment of Neurosurgery, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Shaoju MinDepartment of Clinical Laboratory, The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China.
Peng ZhangDepartment of Urology, Guizhou Provincial People's Hospital, Medical College of Guizhou University, Guiyang, Guizhou, China.
Bin XuDepartment of Urology, Guizhou Provincial People's Hospital, Medical College of Guizhou University, Guiyang, Guizhou, China.
Zhen WangDepartment of Urology, Guizhou Provincial People's Hospital, Medical College of Guizhou University, Guiyang, Guizhou, China.
Wei ZhangDepartment of Urology, Guizhou Provincial People's Hospital, Medical College of Guizhou University, Guiyang, Guizhou, China.
Jiasheng ChenDepartment of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Guangheng LuoDepartment of Urology, Guizhou Provincial People's Hospital, Medical College of Guizhou University, Guiyang, Guizhou, China.
Chunxiao LiuDepartment of Urology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.ORCID https://orcid.org/0000-0001-6676-2495
Guizhou University · CNZhujiang Hospital · CNGuiyang Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the effects of human bone marrow mesenchymal stem cells (hBMSCs) and osteoblasts (hFOB1.19) on PC3 prostate cancer cells.

methodsTo simulate the

resultshBMSCs and hFOB1.19 cells enhanced the proliferation, migration, and invasion of PC3 cells; increased the proportion of PC3 cells in the S and G

conclusionhBMSCs and hFOB1.19 cells modulate the phenotype of PC3 prostate cancer cells and the expression of CD59 by activating the RANK/RANKL/OPG signaling pathway.

Indexed as

Bone and BonesBone MarrowBone NeoplasmsCD59 AntigensCell CycleCell LineCell Line, TumorCell ProliferationHumansMaleNF-kappa BOsteoblastsOsteoclastsPC-3 CellsProstateProstatic NeoplasmsCD59 AntigensCD59 protein, humanNF-kappa B

Identifiers

PMID32337233
PMCPMC7165328
OpenAlexW3014424596

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.